Pharma and Tech Stocks Dominate China A-Share Profit Rankings

Biotech and Computer Stocks Sweep China's Profit Charts

China's A-share market just wrapped up its 2025 annual report season, and the results paint a striking picture: pharmaceutical and computer companies have seized a commanding 80% of the top 50 spots in gross profit margin rankings. For global investors watching China's equity markets, the data underscores a decisive shift toward high-margin, innovation-driven sectors.

Among the top 50 stocks by gross margin, 27 belong to pharma and biotech while 13 come from the computer and IT sector — together accounting for 40 out of 50 positions.

Innovative Drug Makers Lead With Near-Perfect Margins

The 3 highest-ranking stocks all belong to China's booming innovative drug (创新药) segment:

• Haichuang Pharma (688302): 98.62% gross margin
• Shouyao Holdings: 96.93% gross margin
• Aelis Pharma: 96.83% gross margin

These near-99% margins reflect the pricing power of novel therapeutics in China's rapidly expanding pharmaceutical market. All 3 companies carry the '-U' designation on China's STAR Market, indicating they were listed before reaching profitability — a common trait among R&D-intensive biotech firms that have since commercialized breakthrough treatments.

Industry-Level Rankings Reveal Clear Winners and Losers

At the sector level, using the Shenwan industry classification (excluding banking and non-bank financials), the gross margin leaderboard looks notably different from what Western investors might expect:

• Beauty and personal care: Highest sector-wide margin
• Food and beverage: Also above 45% gross margin
• Media: 32.45%
• Pharma and biotech: 32.42%
• Steel: Below 10% (lowest tier)
• Transportation: Below 10% (lowest tier)

Beauty and food sectors leading at the industry level highlights China's consumer pricing power, while individual pharma stocks dominate the top ranks due to the extreme margins of patented drug products.

What This Means for Global Investors

The dominance of pharma and tech in China's margin rankings carries significant implications. China's biotech sector has matured rapidly, with companies transitioning from pre-revenue R&D plays to highly profitable commercial operations. The computer sector's strong showing also reflects growing demand for enterprise software, cybersecurity, and AI-related solutions across Chinese industries.

For international fund managers, several takeaways stand out:

• China's innovative drug pipeline is producing companies with margin profiles rivaling major Western pharma firms like Regeneron or Vertex
• The tech sector's high margins suggest sticky, software-driven revenue rather than low-margin hardware sales
• Traditional industries like steel and transportation remain structurally low-margin, reinforcing the case for sector-selective China exposure

The Bigger Picture: China's Innovation Economy Takes Shape

These rankings offer a data-driven snapshot of China's evolving economic landscape, where innovation-driven sectors are increasingly commanding the highest profit margins across the A-share market.